they had no comment. >> hi, baby. >> reporter: when provigil went generic in 2012, the price for karen winklerom more than $700 to $16 for a three-month supply. winkler was able to go back on the drug, and take the full dose. she says it's made all the difference. >>> how are the courts weighing in on generic drug delays? watch the hangout with ed silverman of the "wall street journal" bloc. visit news hour dot pbs dot org and visit about drug prices. >>> now to the arts and a look at an exhibit here in new york that examines the nazi's efforts to do away with certain works they considered degenerate. the news hour has the report. >> reporter: empty frames and faded imprints aren't what you expect to see at an art show, but in this gallery, they are among the most haunting images, representing the fate of thousands of modern artworks stolen by the nazis in the 1930s, destroyed or remain lost to this day. it's part of an exhibit called "degenerate art on display" until september at the gally in new york offering a new look of assault of modern art by the nazis. the 19th century paintings and sc

. >> because of what critics describe as those pay for delay deals, they didn't go generic so karen winklerd even more because of the second controversial business strategy that they used then and other drug manufacturers continue to use today. something opponents call evergreening. they want to get off the patent. on to new vigil whose patent had several years to run. they do this by jacking up prices on the first drug. that's what happened when speak of the rising price, the doctor offered her new vigil. >> i thought great. here's a solution. came home and i started taking it and got a pounding headache. it was like having a migraine. >> that's when they figured out what was going on. >> they knew it was going to be going in shortly. instead of the ridge is they'll had the team expended, they were not there. it's rare for patients to be switching back. it's a strategy for the brand to hold on to the market even after the generic in the market place. >> this is one=?&p)ea where the pharmaceutical association and the ftc find common ground. >> thas keeping the people who need it and we are